Clinical outcomes and radiation pneumonitis after concurrent EGFR ‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer-Reference-Cited by-同舟云学术

Clinical outcomes and radiation pneumonitis after concurrent EGFR ‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer

Published:2021-01-27 Issue:6 Volume:12 Page:814-823
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Xu Kunpeng¹^ORCID,Liang Jun²,Zhang Tao¹,Zhou Zongmei¹,Chen Dongfu¹,Feng Qinfu¹^ORCID,Xiao Zefen¹,Hui Zhouguang¹^ORCID,Lu Jima¹,Wang Xin¹,Deng Lei¹^ORCID,Liu Wenyang¹,Wang Jianyang¹,Zhai Yirui¹,Wang Jie³^ORCID,Bi Nan¹,Wang Luhua¹²

Affiliation:

1. Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Radiation Oncology National Cancer Center/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13816

Reference31 articles.

1. Clinical Features of 5,628 Primary Lung Cancer Patients

2. Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

3. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer

4. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

5. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC;New England Journal of Medicine;2024-08-15

2. Enhanced radiation sensitivity, decreased DNA damage repair, and differentiation defects in airway stem cells derived from patients with chronic obstructive pulmonary disease;Stem Cells Translational Medicine;2024-06-29

3. Clinical features and outcomes of unresectable locally advanced non-small cell lung cancer with uncommon EGFR Mutations: A retrospective multi-center Chinese study;2024-03-25

5. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives;Lung Cancer;2024-01